trending Market Intelligence /marketintelligence/en/news-insights/trending/3ywzccwdjbu4sojtzkg3vw2 content esgSubNav
In This List

NeuroVive licenses chemistry for inherited vision loss treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


NeuroVive licenses chemistry for inherited vision loss treatment

Sweden's NeuroVive Pharmaceutical AB said it licensed chemistry for its Leber's hereditary optic neuropathy treatment to California-based BridgeBio Pharma LLC.

The deal, which has a total transaction value of about $60 million, covers a subset of succinate prodrug chemistry under NeuroVive's NVP015 clinical program. The amount includes research funding, milestone payments and royalties.

Leber's hereditary optic neuropathy, or LHON, is a genetic condition that causes loss of vision.

BridgeBio said it launched a unit, called Fortify Therapeutics, to further develop the chemistry it acquired for use as local treatment of LHON, with an initial financial commitment of $20 million.

NeuroVive said development of NVP015 for other mitochondrial disorders will continue.